RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC 50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS ( HY-116282C )-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis .
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > Necroptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.